tiprankstipranks
Trending News
More News >
LEOCLAN Co. Ltd. (JP:7681)
:7681
Japanese Market

LEOCLAN Co. Ltd. (7681) AI Stock Analysis

Compare
0 Followers

Top Page

JP:7681

LEOCLAN Co. Ltd.

(7681)

Select Model
Select Model
Select Model
Neutral 51 (OpenAI - 5.2)
Rating:51Neutral
Price Target:
¥903.00
▼(-9.61% Downside)
Action:ReiteratedDate:01/14/26
The score is primarily held back by weak recent cash flow and thin/uneven profitability despite a very strong, low-debt balance sheet. Technicals are slightly negative with the stock trading below major moving averages, and valuation is relatively expensive (high P/E) with only a modest dividend yield.
Positive Factors
Very low debt / strong balance sheet
The company’s near-zero debt and strong capitalization materially lower financial risk and preserve liquidity. That conservative balance sheet gives management durable flexibility to fund operations, absorb shocks, pursue targeted investments or M&A, and avoid forced financing over the next several months.
Recent revenue rebound
A large recent top-line rebound indicates recovering demand or improved commercial execution, providing a base to rebuild margins and operational leverage. Sustained revenue restoration over 2–6 months would support earnings recovery and help restore cash generation if the company maintains sales momentum.
Stable equity capitalization
Stable equity provides a durable capital buffer that reduces solvency risk and supports ongoing operations through cyclical swings. With limited leverage, the equity base enables longer-term planning, conservative reinvestment and the option to access capital without immediate distress even if cash flow remains uneven.
Negative Factors
Deteriorating cash generation
Negative operating and free cash flow in the most recent years shows the business is failing to convert accounting profits into cash. Persisting cash deficits constrain reinvestment, dividend capacity and working-capital flexibility, and raise the probability of needing external financing within a multi-quarter horizon.
Thin and compressed profitability
Very slim net margins reduce the company’s ability to absorb cost increases or competitive pressure, limiting retained earnings for growth. Margin compression versus prior years signals weaker operational leverage and a smaller cushion against shocks, making durable earnings generation more uncertain.
Volatile revenue trajectory
An inconsistent revenue path increases forecasting risk and complicates capacity, inventory and investment planning. The lack of a steady growth trend raises doubt that the recent rebound is structural, exposing the company to potential reversals that would impede margin recovery and cash-flow normalization.

LEOCLAN Co. Ltd. (7681) vs. iShares MSCI Japan ETF (EWJ)

LEOCLAN Co. Ltd. Business Overview & Revenue Model

Company DescriptionLEOCLAN Co.,Ltd. operates as a medical equipment trading company that meets various medical care, welfare, and health needs. It operates through three segments: Medical Total Solutions Business, Remote Image Diagnosis Service Business, and School Lunch Business. The Medical Total Solutions Business segment provides incidental maintenance services; and interior decoration construction and installation works for medical institutions, preventive/health checkup facilities, nursing care/welfare facilities, etc. based on consulting services such as selection of medical equipment, as well as sells medical equipment and medical information systems. The Remote Image Diagnosis Service Business segment offers services in which diagnostic radiology specialists remotely diagnose image data taken by MRI, CT, etc., and provides information. The School Lunch Business segment provides school lunch services, including regular meals, medical meals, and other meals to nursing care and welfare facilities. LEOCLAN Co.,Ltd. was incorporated in 2001 and is headquartered in Settsu, Japan.
How the Company Makes Money

LEOCLAN Co. Ltd. Financial Statement Overview

Summary
Balance sheet strength (negligible debt; strong capitalization) is offset by mixed operating results: volatile revenue, thin/low net margins, and deteriorating cash generation with negative operating and free cash flow in the most recent year.
Income Statement
54
Neutral
Revenue has been volatile: strong rebound in 2025 (annual) after declines in 2023–2024, but the trajectory lacks consistency. Profitability is modest and has compressed versus prior peaks—net margins are low (~0.7% in 2025 vs ~1.5% in 2021–2022), and operating margins remain thin despite a slight improvement in 2025. Overall, the company is profitable, but earnings quality and durability look only average given the uneven top-line trend and slim margins.
Balance Sheet
82
Very Positive
The balance sheet is a clear strength: debt is effectively negligible (debt-to-equity near zero, and zero debt in 2025), which materially reduces financial risk. Equity is stable and supports the asset base, indicating solid capitalization. The main trade-off is that returns on equity have come down meaningfully from earlier years (roughly ~8% in 2021–2022 to ~2–3% in 2024–2025), suggesting the company is currently generating only modest returns despite the conservative leverage profile.
Cash Flow
38
Negative
Cash flow performance is inconsistent and has weakened recently. Operating cash flow turned negative in 2025 after being small but positive in 2024, and free cash flow is negative in both 2024 and 2025, indicating the business is not consistently converting accounting profits into cash. While 2021–2023 showed substantially stronger cash generation, the latest two years raise concern around working-capital swings and/or investment demands pressuring near-term cash returns.
BreakdownSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
Income Statement
Total Revenue21.49B19.80B26.63B29.77B26.35B
Gross Profit2.74B2.62B2.82B3.06B2.73B
EBITDA404.56M373.47M536.93M789.06M692.94M
Net Income152.78M136.06M271.31M437.05M390.98M
Balance Sheet
Total Assets10.87B10.66B14.69B13.47B12.96B
Cash, Cash Equivalents and Short-Term Investments4.78B5.57B5.54B5.48B5.41B
Total Debt7.19M12.57M5.67M99.82M127.10M
Total Liabilities5.05B4.92B8.97B7.93B7.81B
Stockholders Equity5.63B5.57B5.57B5.38B5.03B
Cash Flow
Free Cash Flow-116.70M-3.89M258.41M195.47M1.24B
Operating Cash Flow-86.65M33.08M341.56M242.36M1.30B
Investing Cash Flow-619.82M100.75M-82.01M-49.96M-42.13M
Financing Cash Flow-100.73M-97.22M-202.31M-120.93M-298.01M

LEOCLAN Co. Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price999.00
Price Trends
50DMA
975.50
Negative
100DMA
1003.69
Negative
200DMA
1025.97
Negative
Market Momentum
MACD
-23.37
Positive
RSI
42.62
Neutral
STOCH
32.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7681, the sentiment is Negative. The current price of 999 is above the 20-day moving average (MA) of 924.90, above the 50-day MA of 975.50, and below the 200-day MA of 1025.97, indicating a bearish trend. The MACD of -23.37 indicates Positive momentum. The RSI at 42.62 is Neutral, neither overbought nor oversold. The STOCH value of 32.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7681.

LEOCLAN Co. Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
¥16.21B120.781.24%-33.41%
54
Neutral
¥25.99B-34.16-5.65%-469.19%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
¥5.09B-19.071.67%8.51%12.20%
49
Neutral
¥12.39B-8.14-42.49%-2.37%
45
Neutral
¥7.88B-10.09-93.79%-1332.86%
43
Neutral
¥19.12B-11.3011.34%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7681
LEOCLAN Co. Ltd.
860.00
51.97
6.43%
JP:3750
Cytori Cell Research Institute, Inc.
883.00
-25.00
-2.75%
JP:4599
StemRIM Inc.
305.00
-36.00
-10.56%
JP:4978
ReproCELL Inc.
171.00
10.00
6.21%
JP:7774
Japan Tissue Engineering Co., Ltd.
640.00
189.00
41.91%
JP:7776
CellSeed Inc.
322.00
-50.00
-13.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 14, 2026